Void Research SEMAX and SELANK Promo-Code/Product Detailed FAQ: BOOST30 — Up to 30% Off

Void Research currently lists a neuro-research catalog that includes products associated with SEMAX, SELANK, ADAMAX, and DIHEXA, with some compounds appearing in more than one research-product format. For qualified laboratory buyers trying to understand those listings, the important questions are not simply “Which name sounds strongest?” or “Which product is most popular?” A useful comparison starts with molecular identity, the type and maturity of published evidence, product format, lot documentation, analytical testing, and the difference between vendor descriptions and independently published research.

For qualified research buyers, the current campaign code is BOOST30 for up to 30% off through Void Research with BOOST30.

Affiliate disclosure: This post contains an affiliate link; the publisher may earn a commission from qualifying purchases.

Research-use-only notice: The products discussed here are intended for controlled in-vitro/laboratory research by qualified researchers. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, supplements, cosmetics, or personal experimentation.

This FAQ focuses particularly on SEMAX and SELANK while also explaining why ADAMAX and DIHEXA should not be treated as interchangeable members of one “nootropic peptide” category. Their chemical backgrounds and evidence bases are quite different.

What are SEMAX, SELANK, ADAMAX, and DIHEXA?

The four names frequently appear together in neuro-research catalogs, but grouping them commercially does not make them equivalent scientifically.

SEMAX is a synthetic heptapeptide based on an ACTH-derived sequence. Published research identifies its sequence as Met-Glu-His-Phe-Pro-Gly-Pro. Research on SEMAX spans laboratory, animal, and some human literature, although much of the historical literature comes from Russia and should be interpreted in its original experimental and regulatory context. A PubMed-indexed study, for example, investigated specific SEMAX binding and brain-derived neurotrophic factor changes in rat basal forebrain. That is useful mechanistic evidence, but it does not mean every commercial SEMAX product has been clinically validated or that research findings can be converted into personal-use claims.

SELANK is another synthetic heptapeptide, with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro reported in the literature. Published work has explored several molecular mechanisms, including interactions involving GABA-related binding and peptide-degrading enzymes. Again, mechanistic or experimental observations should be separated from claims about efficacy, safety, or consumer use.

ADAMAX is more complicated. Void Research currently describes its ADAMAX SPRAY listing as an adamantyl-modified SEMAX analogue and provides a proposed molecular description on the commercial product page. However, readers should distinguish that vendor description from the indexed evidence available for SEMAX itself. Searches of the recent secondary literature have highlighted a substantial evidence gap around ADAMAX as an independently studied compound. In other words, evidence about ordinary SEMAX should not automatically be transferred to a chemically modified product merely because it is described as a SEMAX derivative.

DIHEXA belongs to yet another research lineage. Published preclinical work describes it as an angiotensin-IV-derived molecule investigated in relation to hepatocyte growth factor/c-Met signaling, spinogenesis, synaptogenesis, and learning models. The important qualification is that much of the commonly cited DIHEXA evidence is mechanistic, cellular, or animal research rather than evidence supporting routine human use.

That distinction is central to this entire FAQ: catalog proximity is not evidence equivalence.

Does Void Research currently carry SEMAX and SELANK?

Void Research's current spray-category page lists both SEMAX SPRAY and SELANK SPRAY, each identified as a 10 mg spray listing at the time of this source check. The same catalog structure places research products into categories such as sprays, peptides, and several research-interest groupings.

The broader Void Research catalog has also displayed ADAMAX and DIHEXA listings, including multiple format names associated with some of these compounds. Because an online catalog is dynamic, a researcher should treat availability, current presentation, and product-format information as live procurement information rather than permanent scientific characteristics.

A useful earlier companion resource is the Void Research SEMAX, SELANK, ADAMAX and DIHEXA catalog guide, which organizes these names from a catalog perspective. The present FAQ takes a different approach by focusing primarily on the questions a documentation-conscious researcher should ask before comparing individual listings.

What is the main scientific difference between SEMAX and SELANK?

SEMAX and SELANK are both short synthetic peptides containing a Pro-Gly-Pro sequence, but they are not the same molecule and do not have identical research histories.

SEMAX developed from ACTH-fragment research. Several published studies have examined neurotrophic, gene-expression, learning, memory, ischemia-related, and other experimental endpoints. One PubMed-indexed study investigated SEMAX binding in rat basal forebrain and reported changes related to BDNF. Historical literature also describes animal and human investigations, although the quality, design, size, language, and regulatory relevance of individual studies must be considered separately.

SELANK originated through a different peptide-development pathway. Published work has explored GABA-related binding, gene-expression effects, peptide metabolism, and behavioral models. A 2018 review discussed molecular mechanisms proposed to underlie SELANK's observed activity, including experimental findings involving GABA binding. This does not establish that a research-catalog product has an approved therapeutic role.

Older comparative work also examined SEMAX and SELANK in the context of regulatory glyproline peptides and specific biochemical effects. These papers can help explain why the compounds are often discussed in the same research family while still requiring compound-specific interpretation.

Researchers therefore should not reduce the comparison to “SEMAX for one purpose and SELANK for another.” That style of consumer shorthand ignores experimental design, species, assay type, dose conditions, endpoints, and evidence quality.

Does research on SEMAX prove that ADAMAX behaves the same way?

No.

This is one of the most important distinctions in the current catalog discussion.

Void Research describes ADAMAX SPRAY commercially as an “Adamantyl-Semax Analog” and states that it includes structural modifications relative to SEMAX. That description itself means researchers cannot simply assume identical physicochemical behavior or biological activity. A modified molecule requires evidence specific to the modified molecule.

Recent evidence reviews have reported that they could not identify dedicated PubMed-indexed experimental studies of the ADAMAX product identity itself. Those reviews emphasize that ordinary SEMAX literature is parent-compound literature and should not be presented as direct proof of ADAMAX properties.

That matters when evaluating claims such as greater stability, improved penetration, stronger neurotrophic signaling, or longer duration. A chemically plausible hypothesis is not the same thing as a demonstrated property of a commercial research material.

For a research buyer, the appropriate questions become:

What exactly is the molecular identity stated for the lot?

Does the supplier provide analytical evidence consistent with that identity?

Is the evidence being cited about ADAMAX itself, ordinary SEMAX, an unrelated adamantane-containing molecule, or a general chemistry principle?

Those distinctions are more useful than simply treating ADAMAX as “stronger SEMAX.”

How is DIHEXA different from SEMAX and SELANK?

DIHEXA has a distinct research origin.

Published work describes DIHEXA as an angiotensin-IV-derived molecule and has investigated its relationship with the hepatocyte growth factor/c-Met system. A 2014 experimental paper reported that DIHEXA interacted with HGF-related signaling and investigated synaptogenic effects in cell and animal models. The researchers also used learning paradigms in rodents.

Other publications have discussed the development of angiotensin-IV analogues and the HGF/c-Met system as a potential research target. These papers are scientifically interesting, but their preclinical nature is crucial. They should not be rewritten as a claim that DIHEXA is an established treatment for Alzheimer's disease, Parkinson's disease, memory loss, or any other condition.

That is why DIHEXA should not be summarized as simply another version of SEMAX or SELANK. The relevant molecular pathway, development history, and evidence set are different.

For readers wanting a broader comparative discussion, the previously published Void Research SEMAX vs SELANK vs ADAMAX vs DIHEXA research distinctions guide provides a useful companion overview.

Does product format change the molecule's evidence base?

No. Product format and scientific evidence are separate questions.

If a catalog lists a compound as a spray and also as a vial or another laboratory format, the product presentation may change how the material is packaged or prepared for laboratory workflows. It does not automatically generate a new evidence base.

For example, Void Research currently maintains a sprays category that includes SEMAX SPRAY and SELANK SPRAY. The broader catalog has also included ADAMAX and DIHEXA entries.

A useful previously published discussion is the Void Research guide to comparing SEMAX and SELANK spray and vial listings. When reading any format comparison, keep four questions separate:

First, what is the chemical identity?

Second, what is the stated quantity or concentration?

Third, what analytical documentation belongs to the specific lot?

Fourth, what published evidence concerns that molecule rather than the delivery format advertised by a seller?

This prevents a common error in research-product content: turning a packaging distinction into a biological claim.

What should a researcher look for in a Certificate of Analysis?

A Certificate of Analysis, or COA, should be treated as an analytical document associated with a particular material or lot—not as a decorative trust badge.

Void Research states that batches are third-party tested and that COAs are part of its quality-documentation process. Its current site describes multiple testing fields and states that detailed COAs are produced for individual batches and made available through a public archive.

A documentation-conscious reader should first establish that the certificate actually corresponds to the material being evaluated. Useful identifiers may include the product name, lot or batch identifier, testing date, laboratory information, accession or report identifier, and the assays performed.

One example from the current Void Research site shows how a product certificate can distinguish between labeled quantity, measured quantity, purity, identity, test date, assay method, and accession information. That structure illustrates why “99% purity” alone is not a complete analytical story.

Researchers should also understand what different assays answer.

An HPLC purity result generally addresses chromatographic composition under the specific conditions used. It does not by itself prove every aspect of molecular identity.

An identity assay is intended to answer a different question: whether analytical evidence is consistent with the molecule claimed.

Net content or quantitative testing asks whether the amount present is consistent with the stated quantity.

Other quality-control fields may evaluate contaminants, sterility-related parameters, endotoxin, or other characteristics depending on the product and testing program.

A strong documentation review therefore avoids collapsing every result into a single percentage.

Is a 99% purity claim enough to evaluate SEMAX or SELANK?

No.

A high chromatographic purity figure can be useful, but it is one part of product characterization.

Imagine two hypothetical research materials both reported as “99% pure.” Material A has a lot-specific identity result, measured content, test date, accession information, and a certificate traceable to a third-party laboratory. Material B has only a generic web image saying “99% purity.”

Those are not equivalent documentation packages.

Identity matters because purity describes the relative composition of the material detected under an analytical method; it does not necessarily establish that the principal peak corresponds to the expected molecule.

Quantity matters because a chemically pure sample can still contain a different amount of material than the label states.

Lot matching matters because a certificate for a different production lot may tell you little about the vial or research container currently under consideration.

Testing recency and report traceability matter because a buyer needs to know which batch was actually examined.

Void Research currently describes its broader quality system as including multiple analytical checks and batch-linked certificates. Researchers should still read the actual certificate associated with the relevant material rather than relying only on general site-wide statements.

Can SEMAX and SELANK research findings be described as proven human benefits?

That would be too broad.

The evidence landscape contains a mixture of experimental designs and historical literature. Some SEMAX publications report human investigations; others are animal, cellular, biochemical, or molecular studies. SELANK likewise has a mixed research literature.

When a paper observes a molecular change in cultured cells, that is an in-vitro finding.

When a rodent study reports a behavioral or biochemical outcome, that is an animal finding.

When a human study investigates an endpoint, researchers still need to examine the population, control group, randomization, blinding, sample size, outcome measures, publication quality, and regulatory context.

Those evidence levels should not be blended into one marketing statement.

The Void Research evidence-limitations discussion is particularly relevant here because SEMAX, SELANK, ADAMAX, and DIHEXA attract claims that often travel much farther than the underlying studies justify.

A responsible article therefore describes what was studied rather than telling readers what a compound “will do.”

What are the most defensible things to say about SEMAX research?

The safest summary is that SEMAX is a synthetic ACTH-derived heptapeptide with a multi-decade research literature that includes biochemical, animal, and human investigations, while individual findings must be interpreted according to their study design and jurisdictional context.

A PubMed-indexed study reported specific SEMAX binding and changes associated with BDNF in rat basal forebrain. Another historical review described years of experimental development and earlier human investigations. Those records establish that SEMAX has been studied; they do not transform a current U.S. research-catalog listing into an approved medicine.

This distinction is especially important for affiliate content. “There is published SEMAX research” is supportable. “This commercial SEMAX spray will improve your cognition” would cross from describing evidence into a product-specific human benefit claim that the cited research does not establish.

What are the most defensible things to say about SELANK research?

SELANK is a synthetic heptapeptide that has been investigated in experimental work involving neurochemical and behavioral pathways.

A PubMed-indexed review discussed molecular work relating SELANK to GABA binding, while earlier biochemical work examined SEMAX and SELANK effects on enzymes involved in regulatory-peptide degradation.

The important wording is “investigated” or “studied.” Those verbs describe the literature without promising outcomes.

Researchers should also avoid taking a mechanism such as altered receptor binding and automatically translating it into a clinical conclusion. Molecular mechanisms are steps in an evidence chain, not replacements for well-controlled clinical evidence.

What is the biggest evidence limitation for ADAMAX?

The principal issue is the gap between the commercial description of ADAMAX and the amount of independently indexed research specifically studying that modified compound.

Void Research describes its ADAMAX product as a modified SEMAX analogue.

Recent independent evidence reviews, however, have reported no PubMed-indexed experimental literature specifically corresponding to the commercial ADAMAX identity they evaluated. They therefore caution against treating SEMAX studies as if they were ADAMAX studies.

This is not merely academic.

Modification can influence stability, solubility, conformation, binding, distribution, degradation, analytical behavior, and other properties. Even when a modification is introduced with a rational design goal, the resulting molecule needs to be characterized on its own.

Consequently, ADAMAX should be presented as a research-catalog compound with important evidence and identity questions—not as an upgraded version of SEMAX whose superiority has already been demonstrated.

What is the biggest evidence limitation for DIHEXA?

The strongest frequently cited DIHEXA research is preclinical.

Its literature includes mechanistic experiments involving HGF/c-Met signaling, cultured systems, synaptogenesis-related endpoints, and rodent models.

These studies can support discussion of a research hypothesis or mechanism. They cannot support telling a consumer that DIHEXA is established to treat cognitive decline, dementia, neurological disease, or any other medical condition.

This is an important example of why striking experimental results require careful language. A compound can produce an interesting effect in a model and still remain far from demonstrating clinical usefulness or safety.

Are SEMAX, SELANK, ADAMAX, and DIHEXA FDA-approved for the uses discussed here?

The Void Research site explicitly states that its research materials are not approved for human or veterinary use and are intended for controlled in-vitro laboratory research. Its regulatory language also states that its compounds are not intended to diagnose, treat, cure, or prevent disease.

That supplier designation should remain prominent in any discussion of these products.

Historical use or regulatory treatment of a molecule in another country does not automatically create U.S. approval for a particular research product sold online. Likewise, publication of an experiment does not create an approved indication.

Why do researchers need to distinguish “compound evidence” from “supplier evidence”?

Because they answer different questions.

A peer-reviewed SEMAX experiment can tell you something about the compound investigated under that study's conditions.

It does not prove that a specific supplier's current vial contains exactly the expected amount and identity.

A supplier COA can provide analytical information about a particular lot.

It does not prove that the molecule produces a clinical outcome.

A shipping policy tells you about fulfillment terms.

It does not establish legality in every destination.

A product page tells you how the seller currently describes its material.

It does not replace independent scientific characterization.

Keeping these categories separate produces a much more reliable evaluation.

For readers who want a broader overview of the scientific distinctions among these four names, the balanced SEMAX, SELANK, ADAMAX and DIHEXA neuro-research explainer is another useful contextual resource.

What should researchers compare between SEMAX and SELANK product pages?

A practical comparison should begin with documentation rather than promotional adjectives.

Check the exact product name and format.

Check the stated material quantity.

Check whether the relevant lot has a traceable certificate.

Check what assays were performed rather than reading only the headline purity percentage.

Check the test date and laboratory identity.

Check whether the certificate's batch identifier matches the supplied material.

Check whether identity and quantitative content are reported separately from purity.

Check the research-use restrictions.

Check current shipping and return terms if procurement is involved.

Finally, keep scientific literature separate from product documentation. The research paper and the COA perform different jobs.

Does Void Research provide international shipping?

Void Research's shipping policy states that it ships internationally where permitted by law. The policy also states that international shipments are subject to destination-country customs, import, and regulatory requirements and that customs clearance is not guaranteed.

The recipient is identified as the importer of record and is responsible for determining whether a product may legally be imported, possessed, and used in the relevant jurisdiction. Duties, taxes, brokerage charges, VAT/GST, and other destination-country charges may also apply.

The fact that a checkout system accepts an address is therefore not proof of legal importability.

Researchers should treat “international shipping available” and “legal to import in my country” as two completely different propositions.

What happens if customs delays or seizes an international research order?

Void Research's current shipping policy says international packages may be inspected, delayed, detained, returned, abandoned, seized, or destroyed by customs authorities. It also places responsibility for destination-country compliance on the customer and explains its stated policy regarding losses caused by customs action.

That makes pre-procurement legal and institutional review particularly important for laboratories purchasing across borders.

This article cannot determine whether SEMAX, SELANK, ADAMAX, DIHEXA, or another research material is lawful to import into every jurisdiction. Laws and classifications can differ by country and can change.

Does “spray” mean the product is for personal intranasal use?

No.

A product-format name should not override the supplier's research-use restriction.

Void Research describes its compounds as research-grade materials for laboratory use and states that they are not approved for human consumption or medical use. Its research-application language specifies controlled in-vitro laboratory research.

Accordingly, the existence of a “spray” listing should not be interpreted as an instruction to administer the material to a person or animal.

This FAQ intentionally does not provide intranasal administration instructions, dosing, cycles, mixing procedures, reconstitution directions, or personal-use protocols.

Can researchers compare SEMAX, SELANK, ADAMAX, and DIHEXA by “strength”?

“Strength” is usually too vague to be scientifically useful.

Does it mean receptor affinity?

A molecular endpoint?

Concentration?

Stability in a particular experimental environment?

Magnitude of an effect in a specific assay?

Duration in a specific animal model?

A product's labeled amount?

Without defining an endpoint, saying one compound is “stronger” than another can become meaningless marketing language.

These molecules also differ enough that a simple linear ranking would obscure rather than clarify their research profiles.

A better comparison asks which molecular system is being studied, what model is being used, what measurement defines the outcome, how the material was characterized, and whether the relevant literature directly investigated the compound in question.

What should a qualified laboratory buyer verify before ordering?

A concise documentation-first review can prevent many avoidable problems:

1. Confirm the exact product identity and format needed for the planned laboratory work.

2. Locate the relevant lot or batch documentation.

3. Read the actual assay fields rather than relying on a headline purity claim.

4. Distinguish purity, identity, and measured quantity.

5. Confirm that the certificate matches the supplied lot.

6. Review research-use restrictions and institutional policies.

7. For international procurement, review destination-country import rules.

8. Preserve supplier documentation and procurement records for laboratory traceability.

9. Do not treat product-page scientific summaries as substitutes for primary literature.

10. Do not treat parent-compound research as direct proof for a modified analogue.

This approach is particularly important when comparing SEMAX with ADAMAX because their names imply a relationship while their evidence bases are not equivalent.

How does BOOST30 fit into a documentation-first purchase decision?

The promotion should come after, not before, the research and documentation decision.

For a qualified research buyer who has already determined that a Void Research material is appropriate for lawful institutional laboratory work, the campaign code BOOST30 offers up to 30% off.

A discount does not change molecular evidence, analytical quality, legality, or experimental suitability.

That is the right way to integrate a research-product promotion: documentation and research requirements determine whether the material belongs in the procurement workflow; the promotional code affects the commercial transaction.

Can BOOST30 be used for SEMAX or SELANK?

The campaign presented here uses BOOST30 as the Void Research affiliate promo code with an offer of up to 30% off.

The exact campaign destination is the Void Research affiliate link provided near the beginning and again in the final CTA below.

Because catalog composition and commercial terms can change independently of scientific information, researchers should keep promotion questions separate from the scientific comparison. This FAQ therefore does not turn the discount into an efficacy claim or use the offer as evidence that one product is preferable to another.

Does this article recommend SEMAX, SELANK, ADAMAX, or DIHEXA for personal use?

No.

Nothing here is a recommendation for ingestion, injection, intranasal administration, topical application, self-experimentation, veterinary use, diagnosis, prevention, or treatment.

The article discusses supplier listings, analytical documentation, published research, and evidence limitations for qualified research readers.

The distinction is especially important because internet searches for these names often mix laboratory research, clinical terminology, anecdotal reports, product marketing, and self-experimentation discussions. Those categories should not be merged.

Bottom line

SEMAX, SELANK, ADAMAX, and DIHEXA may appear near one another in a neuro-research catalog, but they should not be treated as scientifically interchangeable.

SEMAX has a historical research literature that includes mechanistic, animal, and some human investigations.

SELANK also has published molecular and experimental literature, including work related to GABA-associated mechanisms and regulatory peptide biology.

ADAMAX is commercially described as a modified SEMAX analogue, but its direct independent evidence base is much thinner. SEMAX data therefore should not be presented as proof of ADAMAX performance.

DIHEXA has a separate angiotensin-IV/HGF/c-Met research lineage, with frequently cited evidence centered heavily on mechanistic and preclinical models.

For every compound, a qualified laboratory researcher should separate five things: molecular identity, published evidence, commercial product format, lot-specific analytical documentation, and supplier policy. That framework is far more informative than ranking products by promotional descriptions.

For eligible lawful laboratory procurement, use BOOST30 for up to 30% off through the Void Research BOOST30 research-product destination.

Strict research-use reminder: Void Research products discussed here are for controlled in-vitro/laboratory research by qualified researchers only. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, food, supplements, cosmetics, or personal experimentation.